Akari Therapeutics PLC
NASDAQ:AKTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Akari Therapeutics PLC
NASDAQ:AKTX
|
US |
|
Hongda High-Tech Holding Co Ltd
SZSE:002144
|
CN |
|
Anshin Guarantor Service Co Ltd
TSE:7183
|
JP |
|
Casa Inc
TSE:7196
|
JP |
|
T
|
Turn Therapeutics Inc
NASDAQ:TTRX
|
US |
|
C
|
Cannlabs Inc
OTC:CANL
|
US |
|
X
|
Xinjiang Zhundong Petroleum Technology Co Ltd
SZSE:002207
|
CN |
|
A
|
Aebi Schmidt Holding AG
NASDAQ:AEBI
|
CH |
Akari Therapeutics PLC
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid or leukotriene system and the bioamine system for the treatment of rare and orphan diseases. Its lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4 (LTB4). The company inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement. The company inhibits LTB4 by capturing the fatty acid within the body of the nomacopan protein. The anaphylatoxin (C5a) and the membrane attack complex (MAC) cause and maintain a proinflammatory and prothrombotic state. LTB4 also activates cells via two separate GPCRs and can independently cause and maintain a proinflammatory state.
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid or leukotriene system and the bioamine system for the treatment of rare and orphan diseases. Its lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4 (LTB4). The company inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement. The company inhibits LTB4 by capturing the fatty acid within the body of the nomacopan protein. The anaphylatoxin (C5a) and the membrane attack complex (MAC) cause and maintain a proinflammatory and prothrombotic state. LTB4 also activates cells via two separate GPCRs and can independently cause and maintain a proinflammatory state.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
